Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Sep;6(3):182-4.
doi: 10.1080/14660820510030149.

Cannabinol Delays Symptom Onset in SOD1 (G93A) Transgenic Mice Without Affecting Survival

Affiliations
Comparative Study

Cannabinol Delays Symptom Onset in SOD1 (G93A) Transgenic Mice Without Affecting Survival

Patrick Weydt et al. Amyotroph Lateral Scler Other Motor Neuron Disord. .

Abstract

Therapeutic options for amyotrophic lateral sclerosis (ALS), the most common adult-onset motor neuron disorder, remain limited. Emerging evidence from clinical studies and transgenic mouse models of ALS suggests that cannabinoids, the bioactive ingredients of marijuana (Cannabis sativa) might have some therapeutic benefit in this disease. However, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), the predominant cannabinoid in marijuana, induces mind-altering effects and is partially addictive, compromising its clinical usefulness. We therefore tested whether cannabinol (CBN), a non-psychotropic cannabinoid, influences disease progression and survival in the SOD1 (G93A) mouse model of ALS. CBN was delivered via subcutaneously implanted osmotic mini-pumps (5 mg/kg/day) over a period of up to 12 weeks. We found that this treatment significantly delays disease onset by more than two weeks while survival was not affected. Further research is necessary to determine whether non-psychotropic cannabinoids might be useful in ameliorating symptoms in ALS.

Similar articles

See all similar articles

Cited by 26 articles

See all "Cited by" articles

Publication types

Feedback